{"id":7471,"date":"2025-10-09T23:02:29","date_gmt":"2025-10-09T23:02:29","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/10\/09\/readout-loud-podcast-biotech-peter-marks-eli-lilly-astrazeneca\/"},"modified":"2025-10-09T23:02:29","modified_gmt":"2025-10-09T23:02:29","slug":"readout-loud-podcast-biotech-peter-marks-eli-lilly-astrazeneca","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/10\/09\/readout-loud-podcast-biotech-peter-marks-eli-lilly-astrazeneca\/","title":{"rendered":"Party in biotech land and AstraZeneca\u2019s miscalculation"},"content":{"rendered":"<p>    Party in biotech land and AstraZeneca\u2019s miscalculation<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back?<\/p>\n<p>We discuss all that on this week\u2019s episode of the \u201cThe Readout LOUD,\u201d STAT\u2019s biotech podcast. We bring on Mizuho health care strategist Jared Holz to discuss the rebound in biotech stocks and sentiment.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/10\/09\/readout-loud-podcast-biotech-peter-marks-eli-lilly-astrazeneca\/?utm_campaign=rss\">Read the rest\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein, Elaine Chen, and Allison DeAngelis<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/10\/09\/readout-loud-podcast-biotech-peter-marks-eli-lilly-astrazeneca\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Party in biotech land and AstraZeneca\u2019s miscalculation Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back? We discuss all that on this week\u2019s episode of the \u201cThe Readout LOUD,\u201d STAT\u2019s biotech podcast. We bring on Mizuho health care [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2611,2154,2594,2678,2265],"tags":[2150],"class_list":["post-7471","post","type-post","status-publish","format-standard","hentry","category-astrazeneca","category-biotechnology","category-eli-lilly","category-rare-diseases","category-the-readout-loud","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7471"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=7471"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7471\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=7471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=7471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=7471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}